Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.63 |
| ▸ | GRPR | P30550 | 2/20 | 0.63 |
| ▸ | CALCR | P30988 | 4/20 | 0.60 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | GLP1R | P43220 | 4/20 | 0.58 |
| ▸ | CCKBR | P32239 | 3/20 | 0.58 |
| ▸ | F2 | P00734 | 4/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25460022 | 1.00 | NMBR (0.63) | NMBRGRPRCALCRC5AR1GLP1R | |
| SCHEMBL31038378 | 0.97 | NMBR (0.63) | NMBRGRPRCALCRC5AR1GLP1R | |
| SCHEMBL25845917 | 0.92 | NMBR (0.66) | NMBRGRPRCALCRC5AR1GLP1R | |
| SCHEMBL25845909 | 0.92 | NMBR (0.66) | NMBRGRPRCALCRC5AR1GLP1R | |
| SCHEMBL29496930 | 0.90 | NPY1R (0.62) | GLP1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22807694 | 0.90 | NPY1R (0.62) | GLP1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL25460148 | 0.88 | NMBR (0.65) | NMBRGRPRC5AR1GLP1RCCKBR | |
| SCHEMBL31182914 | 0.87 | CALCR (0.69) | NMBRGRPRCALCRGLP1RCCKBR | |
| SCHEMBL30537029 | 0.87 | GLP1R (0.72) | CALCRC5AR1GLP1RCCKBRNPY1R | |
| SCHEMBL22872738 | 0.87 | NPY1R (0.61) | NMBRGRPRGLP1RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| EP-4615511-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615510-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250135014-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-05-01 | — | — | US | disclosed |
| WO-2024100046-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100044-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135014-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | DCLRE1A, LIG3, LARS1 | NMBR 3776/4885GRPR 1215/4885CALCR 4651/4885 |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | CTDSP1, POLM, MCTS1 | NMBR 4116/4885GRPR 2250/4885CALCR 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.